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Planar cell polarity (PCP) pathways control the orientation and alignment of epithelial cells 
within tissues. Van Gogh-like 2 (Vangl2) is a key PCP protein that is required for normal 
differentiation of kidney glomeruli and tubules. Vangl2 has also been implicated in 
modifying the course of acquired glomerular disease and here we further explored how 
Vangl2 impacts on glomerular pathobiology in this context. Targeted genetic deletion of 
Vangl2 in mouse glomerular epithelial podocytes enhanced the severity of not only 
irreversible accelerated nephrotoxic nephritis but also lipopolysaccharide-induced 
reversible glomerular damage. In each proteinuric model, genetic deletion of Vangl2 in 
podocytes was associated with an increased ratio of active-MMP9 to inactive MMP9, an 
enzyme involved in tissue remodelling. Additionally, by interrogating microarray data from 
two cohorts of renal patients, we report increased VANGL2 transcript levels in glomeruli of 
individuals with focal segmental glomerulosclerosis, suggesting that the molecule may also 
be involved in certain human glomerular diseases. These observations support the 
conclusion that Vangl2 modulates glomerular injury, at least in part by acting as a brake on 
MMP9, a potentially harmful endogenous enzyme. 
 







Van Gogh-like 2 (Vangl2) regulates planar cell polarity (PCP), controlling orientation and 
alignment of epithelial cells within tissues [1]. PCP is implicated in heart [2], lung [3], neural 
tube [4,5] and blood vessel [6] development. In kidneys, Vangl2 is expressed in epithelial 
podocytes in forming glomeruli, the blood ultrafiltration units, and in nephron and collecting 
duct tubules [7,8]. Homozygous Loop-tail mice with Vangl2Lp point mutations have 
malformed kidneys with a paucity of collecting ducts and dysmorphic glomeruli [9,10]. 
Although Vangl2Lp/+ kidneys develop normally, compound heterozygotes harbouring 
Vangl2Lp and a point mutation in another PCP gene, Cadherin EGF LAG seven-pass G-
type receptor 1 (Celsr1), have branching malformations [11]. 
 
PCP is also implicated in acquired kidney disease. Mitotic orientation, a PCP mediated 
process, is aberrant in kidney cystogenesis [12]. Glomerular Vangl2 transcripts increased 
48 hours after initiation of kidney injury by nephrotoxic nephritis (NTN), a progressive 
disease model, and NTN is more severe in mice with podocyte-specific Vangl2 deletion 
[8]. However, how Vangl2 modulates glomerular injury is unclear. Possibly, Vangl2 
attenuates NTN-induced podocyte depletion [8]. Alternatively, Vangl2 might modulate 
tissue remodelling. Indeed, Vangl2 alters activity of matrix metalloproteinases (MMPs). 
Vangl2 downregulation in zebrafish causes increased MMP14 availability, with reduced 
extracellular matrix (ECM) and disrupted convergent-extension [13]. Vangl2Lp/+ mice also 
have both increased Mmp12 transcripts and active protein levels in their lungs [14]. 




upregulated in NTN [17] and experimentally downregulating MMP9 modulates NTN 
[17,18].  
 
We hypothesised that Vangl2 impacts on glomerular disease by modulating MMP. We 
tested this by analysing mouse models of irreversible and reversible glomerular injury, 
both accompanied by leakage of protein into the urine. Irreversible injury was examined in 
NTN mice, analogous to humans with focal segmental glomerulosclerosis (FSGS). 
Injection of lipopolysaccharide (LPS) in mice was used to induce reversible glomerular 
injury, as occurs in humans with minimal change disease (MCD). Our results support the 







All procedures were approved by the UK Home Office. For specific gene deletion in 
glomerular podocytes, we used PodCre mice which express Cre recombinase driven by 
the promoter of podocin, a gene expressed in podocytes from the immature capillary loop 
stage of glomerular development to maturity [19]. Initially, we examined the specificity of 
Cre recombination by breeding PodCre+ mice with R26R-EYFP mice, which have a loxP 
flanked STOP sequence followed by the enhanced yellow fluorescent protein gene (EYFP) 
inserted into the Gt(ROSA)26Sor locus. Subsequently, to delete Vangl2 in podocytes, we 
crossed PodCre+ mice with Vangl2flox/flox mice [20], where loxP sites flank exon 4, with 
PodCre+/Vangl2/flox/+ mice being mated to generate PodCre+/Vangl2flox/flox mice and 
littermate controls, Vangl2flox/flox without Cre. Primers to detect the PodCre, Vangl2flox and 
excised exon 4 of Vangl2 ǻEDQGDOOHOHVDUHGHWDLOHGLQ6XSSOHPHQWDU\ Materials and 
Methods. Recombination of Vangl2 by Cre generates a premature stop codon that gives 
rise to a protein lacking the four trans-membrane domains and the C-terminal PDZ-binding 
domain required for the interaction of Vangl2 with other proteins [21,22]. All transgenic 
mouse strains were on a C57Bl/6 background for >10 generations. 
 
Murine models of glomerular disease  
To induce accelerated NTN [23], a model of irreversible and progressive glomerular 
damage, male PodCre+/Vangl2flox/flox and Vangl2flox/flox mice were pre-immunised by 
subcutaneous injection of sheep immunoglobulin (0.2 mg) in complete Freunds adjuvant. 




EDVHPHQWPHPEUDQH*%0QHSKURWR[LFJOREXOLQȝOILYHGD\s later to induce 
nephritis. Glomerular injury follows with capillary thrombosis and crescent formation [23]. 
 
To induce transient podocyte injury, male PodCre+/Vangl2flox/flox and Vangl2flox/flox mice 
were injected with 10 Pg/g LPS intraperitoneally [24]. C57Bl/6 male wild-type mice were 
also injected with either phosphate buffered saline (PBS) or LPS (n=6 in each group) to 
examine glomerular levels of PCP genes.  
 
Histological analysis 
Kidneys were fixed in 4% paraformaldehyde, dehydrated, wax-embedded and sectioned at 
5 Pm. Periodic acid Schiff (PAS) staining was used to detect basement membranes and 
sclerosis. Glomerular morphology in 12-week old male PodCre+/Vangl2flox/flox and 
Vangl2flox/flox mice was examined by two blinded assessors and designated as normal (little 
PAS-positive material and normal capillary loops) or abnormal (PAS in >50% of the tuft). 
At least 30 glomeruli from four separate mice in each genotype were evaluated. Results 
for each category were expressed as percentage of the total glomeruli assessed. In NTN 
mice, thrombosis (PAS positive areas of occluded capillary loops) was scored using a 
scale of 0-4 depending on the number of quadrants affected within the glomerular tuft 
(each tuft divided into four quadrants for scoring purposes) [23]. Fifty glomeruli were 






Renal function assessment, immunofluorescence staining, Western blotting, 
electron microscopy, podocyte culture and quantitative real-time PCR (qRT-PCR) 
Details are provided in the Supplementary Materials and Methods. 
 
Studies of human kidney tissue 
We interrogated microarray data obtained from microdissected glomeruli from two 
independent cohorts of renal patients. Cohort I was patients with FSGS (n=10), MCD (n=5) 
and living donor (LD) healthy controls (n=18) from the European Renal cDNA Bank [25] 
(Supplementary Table S1) where RNA had been hybridized to Affymetrix HG-U133 Plus 
2.0 microarrays [26]. Cohort II was microarray data from the public domain (GEO 
database: www.ncbi.nlm.nih.gov/geo; project GSE108109; Affymetrix Human Gene 2.1 ST 
arrays). This project includes mRNA expression data from human renal biopsies with 
FSGS (n=16), MCD (n=5) and controls (LDs) (n=6). A single probe-based analysis tool, 
ChipInspector (Genomatix Software GmbH, Munich), was used for transcript annotation, 
total intensity normalisation, significance analysis of microarrays and transcript 
identification based on significantly changed probes [27]. The statistic algorithm in 
ChipInspector is a T-test which creates artificial background data by randomly permuting 
the array results. Each probe has a score on the basis of its fold change relative to the 
standard deviation of repeated measurements for this probe. Probes with scores higher 
than a certain threshold are deemed significant. This threshold is the Delta value. The 
permutations of the dataset are then used to estimate the percentage of probes identified 
by chance at the identical Delta. Thus, a relation of significant probes to falsely discovered 




FDR, a stringency indicator. Analysis was carried out using all default settings as 




Datasets (mean±SEM) were analysed using GraphPad Prism (GraphPad software, La 
Jolla, CA). Differences between two groups were analysed by unpaired t-test. When 
comparing more than two groups, differences were analysed by one-way ANOVA with 
Bonferronis multiple comparison post-hoc tests. Data affected by two variables were 
analysed using two-way ANOVA with Bonferronis multiple comparison post-hoc tests 





Podocyte-specificVangl2 knockdown mice. 
Initially, we examined the specificity of Cre recombination by breeding PodCre+ mice with 
R26R-EYFP mice. In the adult kidneys of PodCre+/R26R-EYFP mice (n=2) we observed 
positive EYFP expression in a pattern typical of podocyte expression in the glomerular tuft 
(Figure S1A). We subsequently bred PodCre+ mice with Vangl2flox/flox mice. 
PodCre+/Vangl2flox/flox and Vangl2flox/flox littermate controls both appeared healthy. DNA 
isolated from the kidney cortex of newborn (postnatal day 1) PodCre+/Vangl2flox/flox mice 
contained both the truncated Vangl2 allele and the intact allele (Figure S1B), consistent 
with Cre-mediated excision in podocytes that themselves represent only a proportion of 
Vangl2 expressing cells in the kidney cortex. We undertook qRT-PCR for Vangl2 on 
RNA isolated from glomeruli of 12-week old PodCre+/Vangl2flox/flox and Vangl2flox/flox mice 
using primers designed to span part of exon 4, finding that Vangl2 transcripts containing 
exon 4 were reduced to 38% in PodCre+/Vangl2flox/flox mice (p<0.05, n=4 each genotype) 
(Figure 1A). As assessed by Western blotting using a C-terminal antibody, Vangl2 protein 
was reduced to 28% in PodCre+/Vangl2flox/flox versus Vangl2flox/flox littermates (p<0.05, n=4 
each genotype) in glomerular lysates from 12-week old mice (Figure 1B, C). The 
remaining Vangl2 expression may be due to inefficient Cre recombination. Alternatively, as 
the mature glomerular tuft also contains endothelia and mesangial cells, Vangl2 might also 
be expressed in these cells. In this regard, we found Vangl2 transcripts in cultured mouse 
endothelia by PCR (Figure S1C). There was no significant difference in glomerular 




(encoding the downstream effector dishevelled associated activator of morphogenesis) 
(Figure S2). 
 
Next, we examined glomerular morphology and function to determine whether Vangl2 is 
required for normal healthy glomeruli. Gross glomerular morphology was assessed in 12 
week old male PodCre+/Vangl2flox/flox and Vangl2flox/flox mice using light microscopy images 
of kidney sections stained with PAS (Figure 1D). Significantly (p<0.05) fewer normal 
(category a) glomeruli were observed in PodCre+/Vangl2flox/flox mice (58.4±6.7%) versus 
Vangl2flox/flox (84.8± 3.1%). Accordingly, the percentage of abnormal (category b) glomeruli 
was significantly (p<0.05) higher in PodCre+/Vangl2flox/flox mice (41.6±6.7%) compared with 
Vangl2flox/flox (15.2± 2.2%) (Figure 1E). There was no significant difference in podocyte 
number between the two genotypes, as assessed by quantifying the number of WT1+ cells 
in at least 30 glomeruli from each mouse (Figure S3). Glomerular ultrastructure was 
assessed by electron microscopy (Figure 1F) and no significant difference was observed 
in GBM or average foot process width between PodCre+/Vangl2flox/flox and Vangl2flox/flox 
mice (Figure 1G-H). To assess glomerular macromolecular barrier function, we quantified 
albuminuria over 24 h (Figure 1I), and to examine excretion of circulating small molecules 
we measured plasma creatinine levels (Figure 1J). No significant differences were 
observed between the two genotypes for either parameter at 12 weeks. 
 
Genetic downregulation of Vangl2 in podocytes worsens experimental nephritis. 
Thus, deletion of podocyte Vangl2 led to modest aberrations of glomerular morphology but 




proceeded to investigate possible roles for Vangl2 in experimentally-induced glomerular 
disease. We first used a model of irreversible and progressive glomerular damage, 
accelerated NTN. Here, mice are pre-immunised with sheep immunoglobulin, and five 
days later nephritis is induced by nephrotoxic globulin (Figure S4A). Previous work has 
shown that glomerular Vangl2 transcripts increased 48 hours after initiation of NTN [8]. 
 
Seven days after disease induction, nephropathic mice displayed a range of glomerular 
abnormalities including capillary thrombosis, mesangial matrix deposition, FSGS and 
glomerular epithelial hyperplasia, the latter representing early crescent formation (Figure 
2A). We found that PodCre+/Vangl2flox/flox mice had significantly increased glomerular 
thrombosis scores compared with Vangl2flox/flox mice (2.0±0.2 versus 1.1±0.3, p<0.02 
(Figure 2B). There was an approximately two-fold higher prevalence of severely damaged 
glomeruli (scores 2-4) in PodCre+/Vangl2flox/flox versus Vangl2flox/flox mice (67.7±7.1% and 
36.2±14.3% respectively, (p<0.05) (Figure 2C). Following NTN, average 24 h albumin 
excretion was significantly increased in Vangl2flox/flox mice versus levels before 
immunisation (p<0.05, Figure 2D). Strikingly, in nephropathic mice, albuminuria was an 
average of 2.5-fold higher in PodCre+/Vangl2flox/flox versus Vangl2flox/flox mice (p<0.01, 
Figure 2D). Plasma creatinine (Figure 2E) levels in the Vangl2flox/flox mice seven days after 
NTN induction were similar to those before immunisation. In nephropathic 
PodCre+/Vangl2flox/flox mice, however, creatinine significantly increased versus levels 
before induction of nephritis (p<0.05). As creatinine is a by-product of muscle metabolism, 
we also measured body weight but found no significant difference between the two 




least 30 glomeruli/mouse and found the average number of podocytes per glomerular area 
was not different between PodCre+/Vangl2flox/flox and Vangl2flox/flox mice with NTN (Figure 
S4C, D). There was also no difference in amounts of IgG deposited within glomeruli 
between nephropathic PodCre+/Vangl2flox/flox and Vangl2flox/flox mice seven days after NTN 
induction (Figure S4E, F), indicating that the difference in disease severity between the 
two groups was not due to changes in glomerular antibody binding. 
 
We also examined whether genetic deletion of podocyte Vangl2 affected immune cell 
infiltration, because this modulates initiation and progression of NTN [28]. We assessed 
numbers of F4/80+ positive macrophages [29] in glomerular tufts (Figure 2F) and in areas 
surrounding glomeruli (Figure 2G). In glomerular tufts before injury, very few F4/80+ 
positive macrophages were detected in either genotype and there was no significant 
change following NTN injury. After induction of nephritis, F4/80+ cells around glomeruli 
increased in Vangl2flox/flox (p<0.01) and PodCre+/Vangl2flox/flox kidneys, though in the latter 
case this did not reach statistically significance (p=0.06), but there was no difference 
between genotypes.  
 
Deletion of Vangl2 in podocytes alters MMP9 during NTN. 
We hypothesised that genetic deletion of Vangl2 in podocytes altered MMP activity, which 
could subsequently contribute to the increased disease severity of NTN observed in 
PodCre+/Vangl2flox/flox mice. Firstly, we knocked-down Vangl2 using siRNA in cultured 
mouse podocytes and measured transcript levels of Mmp2 and Mmp9, both of which have 




Vangl2 mutant lungs [14], and Mmp14, whose availability is elevated in zebrafish with 
Vangl2 downregulation [13]. Vangl2 siRNA resulted in a >90% knockdown in Vangl2 
(Figure 3A), significantly increased mRNA levels of Mmp9 (p<0.05) (Figure 3B) but did not 
affect Mmp2, Mmp12 or Mmp14 (Figure 3C-E) levels (n=3 from at least 3 independent 
experiments analysed in triplicate). We next examined MMP9 expression in detail. MMP9 
was detected on immunohistochemistry at baseline (Figure S5). Following NTN, in both 
Vangl2flox/flox and PodCre+/Vangl2flox/flox mice, MMP9 immunostaining partly spatially 
overlapped with nephrin, a podocyte slit diaphragm protein (Figure 4A-F). Using Western 
blots, we quantified MMP9 in whole kidneys of nephropathic Vangl2flox/flox and 
PodCre+/Vangl2flox/flox mice, probing with an antibody that detects both the inactive form 
(105 kDa; pro-MMP9) and the cleaved, enzymatically active form (95 kDa; active-MMP9) 
(Figure 4G). The average ratio of active MMP9 to pro-MMP9 increased by 40% in 
PodCre+/Vangl2flox/flox versus Vangl2flox/flox tissues (Figure 4H) (6.1±0.4 to 4.4±0.1 
respectively, p<0.05, n=6-11 per group).  
 
We examined expression of collagen IV, an MMP9 substrate [30] and a key GBM 
component [31], using immunofluorescent staining of kidney sections, at baseline and 
during NTN, with an antibody reactive to all collagen IV chains. Quantification was done by 
assigning a score of 0 to glomeruli with staining in <50% of the tuft area and a score of 1 
to glomeruli with staining in >50% of the tuft (Figure 4I, J). There was no significant 
difference between Vangl2flox/flox and PodCre+/Vangl2flox/flox before induction of NTN. During 
NTN, collagen IV score was reduced in both Vangl2flox/flox and PodCre+/Vangl2flox/flox mice 




genotypes (Figure 4M). We also quantified ZO-1, a tight junction protein [32] degraded by 
MMP9 in cultured podocytes [33], by immunofluorescent staining using the same scoring 
system (Figure 4K-L). In nephropathic mice, ZO-1 immunostaining in PodCre+/Vangl2flox/flox 
kidneys was reduced (p<0.02) to approximately half the level measured in Vangl2flox/flox 
organs (Figure 4N). 
 
Podocyte Vangl2 deletion enhances lipopolysaccharide-induced glomerular injury 
and modulates MMP9.  
Next, we determined whether Vangl2 plays a role in another glomerular disease model, 
LPS-induced reversible glomerular injury. Here, podocytes are injured through activation of 
the toll-like receptor 4, leading to foot process effacement within 24-48 h followed by 
resolution after 72 h [24]. One day after LPS administration, urinary albumin/creatinine 
ratio was greater (p<0.05) in PodCre+/Vangl2flox/flox versus Vangl2flox/flox mice by an average 
of 3-fold (Figure 5A). Albuminuria continued to increase in both groups until 48 h, with a 
non-significant (p=0.68) tendency for higher values in PodCre+/Vangl2flox/flox mice 
(2052±ȝJPJversus Vangl2flox/flox DQLPDOVȝJPJ$OEXPLQXULDUHWXUQHG
to basal levels by 72 h in both genotypes. We examined transcript levels of Vangl1, 
Vangl2, Celsr1 and Pk1 in isolated glomeruli 24 h after LPS injury and found no significant 
differences compared with mice injected with PBS (Figure 5B). MMP9 levels in glomerular 
lysates from PodCre+/Vangl2flox/flox and Vangl2flox/flox were assessed using Western blotting 
(Figure 5C, D). In glomeruli harvested from either genotype before administration of LPS 
(n=4-6 in each group), most MMP9 was in the inactive form (Figure 5C) with ratios of 




between the genotypes (Figure 5E). LPS injury in Vangl2flox/flox mice resulted in an average 
ratio of active/pro-MMP9 of 1.2±0.4. Strikingly, the active/pro-MMP9 ratio in 
PodCre+/Vangl2flox/flox LPS glomeruli was 4.3±1.2, significantly higher (p<0.05) versus 
Vangl2flox/flox tissues (Figure 5F). 
 
Levels of PCR transcripts in human glomerular disease.  
To begin to examine the human relevance of this work, we assessed levels of transcripts 
encoded by PCP genes (VANGL1, VANGL2, CELSR1, CELSR2, DISHEVELED 1-3, 
FRIZZLED3, PRICKLE1 and PRICKLE2) in glomeruli from biopsies of individuals with 
either FSGS or MCD from two different cohorts of patients (Table 1). In cohort I, significant 
increases versus healthy controls were observed for all PCP transcripts examined in 
FSGS, including VANGL2 which was upregulated >1.5-fold. Similar findings were 
observed in cohort II with significant increases found in 6 out of the 10 genes evaluated, 
one of which was VANGL2. In contrast, in samples from MCD patients in cohort I, only 
VANGL1 and PRICKLE1 were significantly increased versus healthy kidneys, whereas 
CELSR1 levels were down-regulated by 0.8-fold. There were no significant changes in any 






Targeted genetic downregulation of Vangl2 in podocytes enhanced the severity of both 
accelerated NTN and LPS-induced glomerular damage. In each proteinuric model, genetic 
deletion of Vangl2 in podocytes was associated with an increased ratio of active-MMP9 to 
inactive MMP9. These observations support the conclusion that Vangl2 modulates 
glomerular injury in mice, at least in part by acting as a brake on MMP9, a potentially 
harmful endogenous enzyme. Additionally, by interrogating data from two cohorts of renal 
patients, we report increased VANGL2 transcript levels in glomeruli of individuals with 
FSGS, providing evidence that the molecule may also be involved in certain human 
glomerular diseases. 
 
Previously, we [10] and others [9] showed Loop-tail (Lp) mice with homozygous point 
mutations in Vangl2 had malformed kidneys containing fewer ureteric tree collecting duct 
branches and fewer mature glomeruli. However, the Vangl2Lp/Lp mouse is not an ideal 
model to define the specific glomerular roles of Vangl2. First, the mutation would affect 
Vangl2 in both nephron and collecting duct lineages. Accordingly, because nephron, 
including glomerular, and collecting duct development, are interdependent, the glomerular 
phenotype could be a secondary effect. Secondly, homozygous Lp mutants die neonatally, 
precluding their use in testing roles for Vangl2 in glomerular function and disease in 
adulthood.  
 
To circumvent this, we used a conditional Vangl2flox/flox mouse [19] and deleted Vangl2 




other PCP components in the kidney at the transcriptional level but cannot rule out 
possible differences in their localisation. Indeed, the Lp mutation affects the localisation of 
certain PCP components such as Pk2 [34], Frizzled 3 [21] and Vangl1 [35]. Based on our 
previous observations on the Loop-tail mouse [10] and other evidence supporting a role for 
Vangl2 in podocyte morphology [36], we initially hypothesised that lack of podocyte Vangl2 
might result in impaired glomerular morphology and function. We found the kidneys of 12-
week old PodCre+/Vangl2flox/flox did contain a slight but statistically significant increased 
proportion of morphologically abnormal glomeruli. This is likely explained by the fact that 
podocin promoter driven Cre expression, and thus Vangl2 recombination, would start in 
immature glomeruli, in the capillary loop stage. Kidney function, however, appeared 
preserved in adults as assessed by plasma creatinine and urinary albumin levels. Our 
results concur with Rocque and colleagues [8], who showed that podocyte-specific 
deletion of Vangl2 using the same PodCre line in our study led to smaller glomeruli at two 
weeks of age, but this also did not lead to any changes in albuminuria. Furthermore, 
genetic deletion of podocyte Scribble, encoding another PCP core protein, did not lead to 
any changes in glomerular morphology or function [37]. Collectively, these results suggest 
that knockdown of an individual PCP component does not have a major effect on 
glomerular biology of otherwise healthy mice. On the other hand, our observations on 
Vangl2 and Celsr1 compound heterozygous mice showed a more severe fetal glomerular 
defect than either mouse alone [11]. Future studies on mice lacking multiple PCP 
components could provide more insights into the potential role of this pathway in 





A key finding in our study is that glomerular injury, induced by nephrotoxic serum or LPS, 
is aggravated in mice with genetic downregulation of podocyte Vangl2 compared with 
controls. Although there was no difference in albumin excretion between 
PodCre+/Vangl2flox/flox and Vangl2flox/flox mice before glomerular injury, we cannot rule out 
that the increased proportion of morphologically abnormal glomeruli seen in 
PodCre+/Vangl2flox/flox mice make these animals more susceptible to injury. In future, 
inducing NTN in mice in which Vangl2 is deleted in adulthood by an inducible PodCre 
allele [38] should help unravel whether the above modest glomerular maturation defect is 
playing a confounding role in worsening the severity of nephritis in mice with podocyte-
specific Vangl2 depletion.  
 
How might Vangl2 downregulation lead to enhanced kidney injury? Possible mechanisms 
include cytoskeletal rearrangements affecting cell morphology [39] or changes in 
inflammation [14]. However, in this study, we focused on the effect of Vangl2 
downregulation on MMPs, which modulate tissue remodelling. Firstly, we examined which 
MMPs were altered in cultured podocytes following Vangl2 downregulation and found 
increased transcript levels of Mmp9. Furthermore, in both injury models, Vangl2 mutants 
had increased ratios of active-MMP9 to inactive MMP9. MMP9 has previously been shown 
to be produced by podocytes [16,33], and altered in a number of glomerular diseases 
including lupus nephritis with active, fibrocellular crescents [40], DN [33,41]; viral-
associated glomerulonephritis [42], membranous [43] and hypertensive [44] nephropathy. 
MMP9 is also induced by activation of the toll-like receptor 4 [45,46] which mediates the 




understood. One possibility is through the regulation of vesicular trafficking [13]. 
Alternatively, Vangl2 can regulate cell VXUIDFHLQWHJULQĮYȕH[SUHVVLRQDQGDGKHVLRQWR
fibronectin, laminin and vitronectin [47].  
 
We subsequently examined some of the mechanisms through which increased MMP 
activity might aggravate glomerular disease in NTN. MMPs were originally characterised 
by their ability to break down ECM [48], therefore we examined collagen IV, a key 
component of the glomerular ECM [31]. However, we did not find any difference in 
collagen IV expression between PodCre+/Vangl2flox/flox and Vangl2flox/flox animals with NTN. 
Recent studies using proteomic approaches have shown that the glomerular ECM is 
composed of over 140 structural and regulatory components [49] and future experiments 
could examine the detailed ECM proteome of nephropathic PodCre+/Vangl2flox/flox and 
Vangl2flox/flox animals. LPS injury in mice also results in remodeling of the GBM 24 h later. 
A glomerular microarray study found elevated levels of transcripts encoding collagen IV D1 
and D2 chains alongside laminin D5E2J1 [50] both of which normally predominate in 
immature glomeruli [51]; we postulate that MMP9 may play a role in this process. 
 
In vitro, podocyte exposure to exogenous MMP9 was shown to degrade ZO-1, a tight 
junction protein [32]. We also examined the distribution of ZO-1 in vivo following NTN and 
found a significant reduction in PodCre+/Vangl2flox/flox mice. Ultrastructure assessment of 
rat kidneys with NTN has shown that tight junction formation is an early abnormality in 




postulated that podocyte-to-podocyte tight junction function may be a compensatory 
mechanism to maintain glomerular filtration barrier integrity. Therefore, the loss of ZO-1 in 
PodCre+/Vangl2flox/flox mice with NTN may lead to filtration barrier disruption and account 
for the enhanced albuminuria seen in these mice. MMP9 has also been shown to up-
regulate podocyte integrin linked kinase (ILK) secretion [33], a kinase known to induce 
podocyte de-differentiation and detachment in disease conditions [53]; whether it is up-
regulated in the setting of dysfunctional PCP remains to be elucidated. Further studies 
inhibiting MMPs in PCP deficient mice would help to delineate their role in this pathway. 
Chemical inhibition of MMP activity has already been shown to be beneficial in some 
models of glomerular damage [54,55] and based on our observations we would predict a 
similar role in dysfunctional PCP-associated glomerular damage. 
 
To begin to examine the relevance of our mouse studies to human disease, we examined 
PCP transcripts in microdissected glomeruli from FSGS and MCD patients. In data from 
two independent cohorts of FSGS patients, significant increases versus living donors were 
observed for the majority of PCP transcripts examined. Importantly, in both FSGS cohorts 
VANGL2 was upregulated >1.5-fold, suggesting this molecule may have an important 
biological role in FSGS. It should be noted that there were some discordant results 
between the two cohorts analysed (for example in the number of PCP transcripts found to 
be significantly altered) and follow-up studies should confirm the microarray data by qRT-
PCR and assess VANGL2 at the protein level in human glomeruli. In accord with the 
human data, a significant upregulation of Dvl2, Fz3, Pk1 and Vangl2 glomerular transcripts 




glomerular ECM deposition are a feature of FSGS and NTN [56,57] whereas in MCD or 
LPS glomerular disease, where there is no sclerosis or excess ECM deposition, the 
majority of PCP genes examined were unaltered. Collectively, the finding of VANGL2 
upregulation in FSGS coupled with the observation that glomerular disease is worsened in 
mice deficient for Vangl2 in podocytes, suggests that increased PCP gene expression in 







Figure 1. Podocyte-specific Vangl2 knockdown is associated with glomerular 
dysmorphology but no impairment of kidney function. (A) Vangl2 mRNA expression in 
glomerular isolates of Vangl2flox/flox and PodCre+/Vangl2flox/flox mice by RT-qPCR (n = 4). 
(B) Representative western blot of glomerular lysates isolated from adult 
PodCre+/Vangl2flox/flox and Vangl2flox/flox mice (n = 4 per genotype). (C) Semi-quantitative 
densitometric analysis shows that Vangl2 protein in PodCre+/Vangl2flox/flox mice is reduced 
(p<0.05) compared with littermate Vangl2flox/flox controls. (D) Representative images of 
category (a)-normal and (b)-abnormal glomeruli used to assess glomerular morphology, 
scale bar = 20 Pm. Normal glomeruli contain numerous patent capillary loops surrounded 
by a thin basement membrane stained red by PAS (arrows) whereas abnormal glomeruli 
have fewer patent capillary loops and increased PAS staining (arrows in b). (E) 
PodCre+/Vangl2flox/flox mice had fewer normal (category a) glomeruli than Vangl2flox/flox 
controls and more category b glomeruli, (p< 0.05, n = 4 in each genotype, 30-50 
glomeruli/sample). (F) Transmission electron micrographs of representative glomeruli from 
the two genotypes. Endo = endothelial cell; pod = podocyte; GBM = glomerular basement 
membrane; FP = foot process. Magnification= x10500. Quantification of GBM width (G) 
and average foot process width (H) (n = 4 in each genotype, 10 images/sample). (I) 24 h 
albumin excretion in urine of Vangl2flox/flox (n = 12) and PodCre+/Vangl2flox/flox mice (n = 12) 
collected at 12 weeks. (J) Plasma creatinine concentration in Vangl2flox/flox (n = 8) and 
PodCre+/Vangl2flox/flox mice (n = 11) at 12 weeks of age. All values are presented as mean 





Figure 2. Podocyte-specific Vangl2 knockdown exacerbates glomerular sclerosis and 
albuminuria following nephrotoxic nephritis. (A) Representative images of PAS-stained 
glomeruli used to score thrombosis, scale bar = 20 Pm. Arrows show areas of thrombosis 
(occluded capillary lumens) and * indicates a glomerular crescent. (B) Thrombosis score 
was higher and a greater percentage of glomeruli were severely affected (C) (categories 2-
4) in PodCre+/Vangl2flox/flox mice compared with controls (n = 6-11 in each group, 50 
glomeruli/sample). (D) 24 h albumin excretion in urine and (E) plasma creatinine 
concentration, n = 6-11. Quantification of F4/80+ cells in the glomerular tuft (F) and peri-
glomerular area (G) of Vangl2flox/flox and PodCre+/Vangl2flox/flox mice (n = 6-11 in each 
group, 30 glomeruli/sample). All values are presented as mean ± SEM, ns = not 
significant. 
 
Figure 3. Vangl2 siRNA knockdown increases Mmp9 mRNA levels. Podocytes grown 
in vitro under permissive conditions were differentiated for 14 days before being 
transfected with control siRNA or siRNA targeting Vangl2. (A) Quantification of Vangl2 
mRNA levels in podocytes 48 h after transfection. Relative mRNA levels of Mmp9 (B) 
Mmp2 (C), Mmp12 (D) and Mmp14 (E). Experiments were repeated 3 to 4 times and 
results are expressed as mean ± SEM. ns = not significant. 
 
Figure 4. Podocyte-specific Vangl2 knockdown increases MMP9 activity following 
nephrotoxic nephritis. (A-F) Representative pictures of immunostaining for MMP9 (A and 




PodCre+/Vangl2flox/flox mice (upper and lower panel respectively) following administration of 
nephrotoxic serum. Arrowheads indicate areas of overlapping podocyte staining in both 
genotypes. (G) Representative western blot for MMP9 from whole kidney lysates 7 days 
after NTN induction. (H) The ratio of active MMP9 to pro-MMP9 in PodCre+/Vangl2flox/flox 
mice is increased compared with Vangl2flox/flox controls, p<0.02, n= 6-11 in each group. (I-
J) Representative images of collagen IV stained glomeruli scored 0 or 1. Arrowheads show 
positive staining in the glomerular tuft arising from the GBM surrounding the capillary 
loops. (K-L) Representative images of ZO-1 stained glomeruli scored 0 or 1. Arrowheads 
show positive staining in the glomerulus. (M) Quantification of Collagen IV and (N) ZO-1 
staining at baseline and following NTN, expressed as average score per glomerulus, in 
Vangl2flox/flox and PodCre+/Vangl2flox/flox mice (n = 6-11 in each group, 30 
glomeruli/sample). All values are presented as mean ± SEM, ns = not significant. 
 
Figure 5. Podocyte-specific Vangl2 knockdown exacerbates albuminuria and increases 
MMP9 activity following LPS injury.  (A) 8-10 week-old mice were injured with LPS (10 
Pg/g) and albuminuria was measured at 24, 48 and 72 h. PodCre+/Vangl2flox/flox mice had 
higher urine albumin to creatinine ratio at 24 h compared to Vangl2flox/flox controls (n = 5-6 
per genotype), p< 0.05 by two way ANOVA and Fishers least square difference test. (B) 
qRT-PCR of core PCP genes in isolated glomeruli following injury with LPS or PBS. 
Representative immunoblot of MMP 9 (active and pro) in glomerular lysates from 
Vangl2flox/flox and PodCre+/Vangl2flox/flox mice prior to (C) and (D) 24 h following LPS. 




PodCre+/Vangl2flox/flox mice compared to Vangl2flox/flox controls (n = 5-6 per genotype). All 
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Table 1. Levels of PCP transcripts are altered in human glomerular disease. 
  





FSGS (n=10) vs 
LDs (n=18) 
MCD (n=5) vs 
LDs (n=18) 
FSGS (n=16) vs 
LDs (n=6)  
MCD (n=5) vs 
LDs (n=6)  
81839 VANGL1 1.37 1.24 1.68 ns 
57216 VANGL2 1.53 ns 1.66 ns 
9620 CELSR1 1.06 0.78 ns ns 
1952 CELSR2 1.28 ns 2.08 ns 
1855 DVL1 1.25 ns ns ns 
1856 DVL2 1.24 ns 1.70 ns 
1857 DVL3 1.23 ns 1.69 ns 
7976 FZD3 1.27 ns ns ns 
144165 PRICKLE1 1.31 1.34 1.71 ns 
166336 PRICKLE2 1.30 ns 0.83 ns 
 
Single probe analysis for selected PCP transcripts in microdissected glomeruli from two 
independent cohorts of renal patients with focal and segmental glomerulosclerosis 




Values are expressed as fold change compared to LD Significantly upregulated genes are 
shown in red and downregulated in blue. Transcripts with a fold change above 1.5 or 
below 0.667 are displayed in bold.  
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